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Introduction
Radioligand binding assays are widely used to measure levels of neurotransmitter receptors in the post-mortem central nervous system (CNS) (Dean et al., 2001; Pralong et al., 2000; Zavitsanou et al., 2004) . The cholinergic muscarinic receptors (CHRM) have been implicated in the pathophysiology of several psychiatric illnesses, including bipolar disorders (BPD) (Cannon et al., 2006) , major depressive disorders (MDD) (Comings et al., 2002) and schizophrenia (Raedler et al., 2003) , and several radio-labelled antagonists have been used to measure levels of the different CHRMs (Crook et al., 1999 (Crook et al., , 2001 Gibbons et al., 2009 (Egan, 2012) .
[ 3 H]4-DAMP binds with high affinity to CHRM3 but competition binding studies using the CHRM1 antagonist pirenzepine have shown that it also binds to CHRM1 (Araujo et al., 1991; Michel et al., 1989; Pinter et al., 1999) . Araujo et al. (1991) reported Kd binding affinities of 0.14 to 0.53 nM for CHRM3 and 50 to 59 nM for CHRM1 in the in cortical and subcortical regions of the rodent brain suggestive of high and low affinity [ 3 H]4-DAMP binding sites, respectively. However, other studies suggest that CHRM3 and CHRM1 bind with similar affinity reporting Kd values of 4 nM for both receptors in the rodent frontal cortex (Zubieta and Frey, 1993) . Such differences may be a result of the differing approaches to characterising the binding sites which examined competition binding at a single (Zubieta and Frey, 1993) (Levey, 1993; Oki et al., 2005; Wei et al., 1994) .
Within the frontal cortex, CHRM1 and CHRM3 show similar levels of RNA expression with CHRM3 expression predominantly localised to the superficial of deep layers of the cortex while only slight of expression levels is apparent for CHRM1 (Buckley et al., 1988; Wei et al., 1994) . However, CHRM1 and CHRM3 protein expression in the frontal cortex is reported to be 25% and 7% of population of CHRMs, respectively (Buckley et al., 1988; Levey et al., 1994) . Thus, there is the potential for changes in low affinity binding to these targets radioligands to affect receptor density estimates based on high affinity binding alone.
We have previously reported a reduction in [
